|
IQVIA™ Real-World Insights Bibliography
| The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
|
| Author(s): Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens
Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore,
Aida Aydemir, Irene Bezemer & Meritxell Sabidó
|
| Affiliations(s): "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia;
b The Alfred Hospital, Melbourne, VIC, Australia;
c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;
d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland;
e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany;
f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland;
g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland;
h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway;
i Department of Clinical Medicine, University of Bergen, Bergen, Norway;
j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
l Bordeaux PharmacoEpi (BPE), Universit�e de Bordeaux, Bordeaux, France;
m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA;
n Global Epidemiology, IQVIA, Amsterdam, The Netherlands;
o Merck Healthcare KGaA, Darmstadt, Germany"
|
| Publication(s): |
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders,
2023 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Population Based Study, |
|
 |
| |
| |
| The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets |
| Author(s): Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group |
| Affiliations(s): 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
2The Alfred Hospital, Melbourne, Australia.
3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France.
4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA).
5Global Database Studies, IQVIA, Tartu, Estonia.
6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands.
7IQVIA (former EPID Research), Espoo, Finland.
8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. |
Publication(s): Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977
|
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Drug safety, Neurological disorders,
2022 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus and Influenza Related Hospitalizations in Adults – A Global Study During the 2017-2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study) |
| Author(s): Ann R Falsey, Edward E Walsh, Stacey House, Yannick Vandenijck, Xiaohui Ren, Sofia Keim, Diye Kang, Pascale Peeters, James Witek, Gabriela Ispas |
| Affiliations(s): University Of Rochester School Of Medicine and Rochester Regional Health, Rochester, NY, United States; Washington University School of Medicine, St Louis, MO, United States; Janssen Infectious Diseases, Beerse, Belgium; IQVIA Real-World Solutions, Courbevoie, France; Janssen Research & Development, LLC, Titusville, NJ, United States |
| Publication(s): |
| Document Type(s): Article, |
| Countries: Argentina, Australia, Brazil, Canada, France, Germany, Japan, Korea, Malaysia, Mexico, South Africa, USA, |
| Click here for the abstract |
C:
Y: |
Infectious disease,
2021 |
|
L:
A: |
English
Burden of illness, Clinical setting: hospital, Epidemiological study, Observational study, Patient questionnaire, Prospective study, |
|
|
| |
| |
| Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer |
| Author(s): Gomez-Ulloa D1, Amonkar M2, Kothari S3, Cheung WY4, Chau I5, Zalcberg J6, Lara N1, Falcone A7 |
| Affiliations(s): 1 IQVIA, Barcelona, Spain 2 Merck & Co., Inc., North Wales, PA, US 3 Merck & Co., Inc., Kenilworth, NJ, US 4 British Columbia Cancer Agency, Vancouver, BC, Canada 5 Royal Marsden Hospital, London, UK 6 Alfred Health, Melbourne, Australia 7 University of Pisa, Pisa, Italy |
Publication(s): BMC Gastroenterology
BMC Gastroenterology volume 20, Article number: 133 (2020)
|
| Document Type(s): Article, |
| Countries: Australia, Canada, Italy, UK, |
| Click here for the abstract |
C:
Y: |
Oncology,
2020 |
|
L:
A: |
English
Retrospective cohort analysis, |
|
|
| |
| |
| Investigation of factors considered in the health technology assessment conducted by regulatory authority in eight countries |
| Author(s): Akira Yuasa 1, Naohiro Yonemoto 1, Sven Demiya 2, Chihiro Foellscher 2, Shunya Ikeda 3 (rwesheorj 2) |
| Affiliations(s): 1) Pfizer Japan Inc., Tokyo, Japan
2) IQVIA Solutions Japan, Tokyo, Japan
3) Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan |
Publication(s): ISPOR 2020 Conference
|
| Document Type(s): Abstract, |
| Countries: Australia, Canada, France, Germany, Italy, Japan, Spain, UK, |
| Click here for the abstract |
C:
Y: |
2020 |
|
L:
A: |
English
|
|
|
| |
| |
| Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients |
| Author(s): Skelly A1, Bezlyak V1, Liew G2, Kap E3, Sagkriotis A1 |
| Affiliations(s): 1. Novartis Pharma AG, 4002 Basel, Switzerland; 2. Westmead Institute for Medical Research, University of Sydney, Westmead NSW 2145, Australia; 3. IQVIA Commercial GmbH & Co. OHG, 60549 Frankfurt, Germany |
| Publication(s): |
| Document Type(s): Article, |
| Countries: Australia, |
| Click here for the abstract |
C:
Y: |
Ophthalmology,
2019 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis, |
|
|
| |
| |
| Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC) |
| Author(s): Amonkar M1, Gomez-Ulloa D2, Smita Kothari1, Cheung WY3, Chau I4, Zalcberg JR5, Lara N2, Falcone A6 |
| Affiliations(s): 1 Merck & Co., Inc., Kenilworth, NJ, USA 2 IQVIA, Barcelona, Spain 3 British Columbia Cancer Agency, Vancouver, BC, Canada 4 Royal Marsden Hospital, London, UK 5 Alfred Health, Melbourne, Australia 6 University of Pisa, Pisa, Italy |
Publication(s): BMC Gastroenterology volume 20, Article number: 133 (2020)
|
| Document Type(s): Poster, |
| Countries: Australia, Canada, Italy, UK, |
C:
Y: |
Oncology,
2019 |
|
L:
A: |
English
Retrospective cohort analysis, |
|
|
| |
| |
| Clinical Characteristics of 3,030 Glioblastoma Multiforme (GBM) Patients in High, Upper Middle and Lower Middle Economic Regions Based on Real-World Data (RWD) |
| Author(s): Mitrofan L1 , M.R. Krukas-Hampel M.R2 , L.A. Mendoza L.A3 |
| Affiliations(s): IQVIA, Paris, FR; IQVIA New York, US; IQVIA, Prague, CZ |
Publication(s): ESMO 2018
|
| Document Type(s): Poster, |
| Countries: Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK, |
C:
Y: |
Oncology,
2018 |
|
L:
A: |
English
|
|
|
| |
| |
| Clinical characteristics of Glioblastoma Multiforme (GBM) Patients Who Reached 400 Days Post Diagnostic from a Retrospective Real-World Data |
| Author(s): Mitrofan L.M.1,Krukas-Hampel M.R.2, Mendoza L.A.3 |
| Affiliations(s): 1 IQVIA, Paris, FR; 2IQVIA New York, US; 3IQVIA, Prague, CZ |
Publication(s): ESMO 2018
|
| Document Type(s): Poster, |
| Countries: Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK, |
C:
Y: |
Oncology,
2018 |
|
L:
A: |
English
|
|
|
| |
| |
| Identifying the confuonders that explain the difference in readouts between non-interventional and randomized controlled trials: the case of treatments in neovascular age-related macular degeneration |
| Author(s): Sakriotis A1, Griner R2, Durus A1, Doyle OM2, Rodriguez-Torres L1, Wintermantel T2, Clemens A13 |
| Affiliations(s): 1. Novartis Pharma AG, Basel, Switzerland; 2. IQVIA Real World Insights, Switzerland/UK/US; 3. Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany |
Publication(s): ISPOR Europe, Barcelona, Spain, 10-14 November 2018
|
| Document Type(s): Poster, |
| Countries: Australia, UK, USA, |
C:
Y: |
Ophthalmology,
2018 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis, |
|
|
| |
| |
 1 of 5 
|
|
